Hopp til innhold
VIS logo Logo for VIS
Visinnovasjon.no > Aktuelt > BerGenBio appoints non-executive directors

BerGenBio appoints non-executive directors

BerGenBio AS has appointed Hilde Furberg and Dr Stener Kvinnsland as Non-Executive Directors to its Board of Directors, effective immediately.

Dr Stener Kvinnsland has more than 30 years of experience in oncology. He is Chair of Board, Oslo University Hospital. Among Dr Kvinnsland’s previous roles, he was Chief Executive Officer of the Bergen Hospital Trust (Helse Bergen), Head of the Department of Oncology and Medical Physics at Haukeland University Hospital, Professor of Medicine (Oncology) at the University of Bergen and Director Clinical R&D, Oncology for Pharmacia & Upjohn in Milan.

Hilde Furberg has over 30 years of experience in pharma and biotech and is currently Senior Vice President Rare Diseases EMEA at Genzyme, a Sanofi company. Previously her role was Vice President and General Manager of Nordic Benelux and Nordic General Manager at Genzyme. Prior to joining Genzyme, Ms Furberg was Managing Director and part-owner of Pharmalink A/S and held a number of roles at Baxter including Managing Director, Sweden. She is currently a board member at Pharmalink AB and has held board positions at Algeta ASA, Clavis, Pronova and Probi AB.

– I am delighted that Hilde and Stener will be joining our Board of Directors. With experience of the pharmaceutical industry and drug development, they are very welcome additions to the Board. I look forward to working with them both as we continue to grow BerGenBio,  said Richard Godfrey, Chief Executive Officer of BerGenBio, commenting on the appointments.

BerGenBio is one of BTO’s first successful companies. The company is dedicated to deliver specialized cutting-edge cancer research to the global biotechnology and pharmaceutical industry. It was established in 2007 by BTO, Unifob AS and researches from the Department of Biomedicine at University of Bergen.

The researchers are focused on developing novel therapeutics for cancers that are aggressive and have become resistant to therapy. Their potential success could prove to be a medical breakthrough, as 90 percent of all cancer related deaths are due to this type of aggressive and resistant cancer.

Read more here

Picture: Stener Kvinnsland and Hilde Furberg (Photo: Helse Bergen)